Agios Pharmaceuticals, Inc.

Company Listings from SPi: Agios Pharmaceuticals, Inc.

You are here: Home >> SPi Company Listings >> Agios Pharmaceuticals, Inc.

 

Agios Pharmaceuticals, Inc.

Website:
http://

Search for other references to "agios" on SPi News

Latest Agios Pharmaceuticals, Inc. News

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemother CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic dise...... 20:00 GMT Tuesday 26th March 2019

Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic dise...... 12:00 GMT Monday 4th March 2019

Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients MUNICH, Germany, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseas...... 12:00 GMT Monday 25th February 2019

Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic disea...... 12:00 GMT Thursday 21st February 2019

Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic disea...... 12:00 GMT Wednesday 20th February 2019

Agios Reports Fourth Quarter and Full Year 2018 Financial Results CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic dise...... 12:00 GMT Thursday 14th February 2019

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019 CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic dise...... 12:00 GMT Thursday 31st January 2019

Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic disease...... 12:00 GMT Monday 7th January 2019

Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 CAMBRIDGE, Mass., Dec. 28, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic disea...... 12:00 GMT Friday 28th December 2018

Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS) SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, to...... 15:30 GMT Monday 3rd December 2018

Buy Agios Pharmaceuticals, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us